All PatientsAdalimumabEtanercept
N550166384
Females68%59%71%
Age (years), median (IQR)12 (8-14)12 (10-14)11 (8-14)
Disease duration (years), median (IQR)1 (1-4)1 (0-3)1 (1-4)
ILAR
Persistent oligo9%6%11%
Extended oligo20%14%23%
RF negative37%32%39%
RF positive11%11%12%
Psoriatic5%8%4%
Enthesitis-related16%27%11%
Undifferentiated1%2%1%
Concomitant oral steroids16%20%15%
Concomitant methotrexate72%84%66%
Follow-up time, years
Median (IQR)2.5 (1.4-3.8)2.1 (1.2-3.1)3.0 (1.6-4.0)
Min-Max0.4 - 8.20.4 - 7.30.4 - 8.2
Drug Survival
Still on drug at one year70%67%71%
Still on drug at two years47%50%46%
CHAQ
Baseline, mean (SE)0.9 (0.04)0.8 (0.06)1.0 (0.04)
One Year, mean (SE)0.7 (0.03)0.5 (0.06)0.7 (0.04)
Change, mean (SE)-0.2 (0.04)-0.2 (0.06)-0.2 (0.04)
Regression coef (95% CI)--0.09 (-0.2, 0.04)Ref
PD Adjusted coef (95% CI)--0.08 (-0.2, 0.07)Ref
MCID (CHAQ)
Proportion achieved48%48%48%
OR (95% CI)-1.0 (0.6, 1.5)Ref
PD Adjusted OR (95% CI)-1.2 (0.8, 1.9)Ref
JADAS
Baseline, mean (SE)14 (0.4)14 (0.7)14 (0.4)
One Year, mean (SE)5 (0.3)4 (0.5)6 (0.3)
Change, mean (SE)-9 (0.4)-9 (0.7)-8 (0.5)
Regression coef (95% CI)--1.1 (-2.3, -0.01)*Ref
PD Adjusted coef (95% CI)--1.0 (-2.8, 0.8)Ref
Inactive Disease (JADAS<1)
Proportion achieved26%32%24%
OR (95% CI)-1.5 (1.0, 2.4)Ref
PD Adjusted OR (95% CI)-1.5 (0.9, 2.4)Ref
Minimal Disease Activity (MDA) [excludes enthesitis-related JIA]
N=473

N=121

N=352
Proportion achieved46%49%45%
OR (95% CI)-1.2 (0.8, 1.9)Ref
PD Adjusted OR (95% CI)-1.2 (0.8, 2.0)Ref
  • Childhood Health Assessment Questionnaire (CHAQ), confidence interval (CI), International League Against Rheumatism (ILAR), interquartile range (IQR), odds ratio (OR), propensity decile (PD), rheumatoid factor (RF), standard error (SE). *p<0.05